Congratulations to the NIDA labs who participated and received awards in the 2023 NIH Green Labs Program! Molecular Neuropsychiatry Section, Adjei, Nasser – Gold Translational Analytical Core, Kryszak, Lindsay – Silver Neuronal Circuits and Behavior Section, Sarsfield, Sarah – Silver Integrative Neuroscience Research Branch, Neuronal Networks Section, Barbano, Flavia – Bronze Molecular Targets and Medications… [Read More]
Hot Off the Press
A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site.
Hot Off the Press – October 15, 2024 Published in Nature Communications with contributions from Alessandro Bonifazi , Francisco Battiti and Amy Hauck Newman of the NIDA IRP Medicinal Chemistry Section. Summary We have been designing bitopic ligands for more than two decades with the idea that the secondary pharmacophore would bind in a site… [Read More]
Reviews To Read
Morphinan Alkaloids and Their Transformations: A Historical Perspective of a Century of Opioid Research in Hungary
Reviews To Read – July 2025. Published in International Journal of Molecular Sciences with contributions by Kenner Rice of the NIDA IRP Drug Design and Synthesis Section. The word opium derives from the ancient Greek word ὄπιον (ópion) for the juice of any plant, but today means the air-dried seed capsule latex of Papaver somniferum. Alkaloid… [Read More]
Featured Papers
Latent Classes of Adverse Childhood Experiences (ACEs) and Adult Substance-use Problems and Psychosocial Outcomes: Complex and Heterogeneous Associations.
Featured Paper of the Month – February 2026
Published in International Journal of Mental Health and Addiction by Emily Herberholz, Rachel Wolchok an David Epstein, et al. of the NIDA IRP Real-world Assessment, Prediction, and Treatment Section.
In this paper, we first showed that we could categorize people by specific patterns/types of ACE exposure, providing a more informative summary than the older approach of just tallying up each person’s total number of types of ACEs. Then we showed that even though ACE exposure can predict later SUD symptoms to a statistically significant degree in people who use alcohol or other drugs, the predictions are too imprecise for case-by-case decision-making
